Gilead Sciences has agreed to acquire CV Therapeutics (CVT) for US$1.4 B - trumping Astellas’ hostile bid. The acquisition will complement and extend Gilead’s reach in cardiovascular medicines. The board of CVT has approved the bid at US$20 a share and it is unlikely that Astellas will go higher and initiate a bidding war.